| 张晓青,孙素真,唐洪侠,杜雅坤,刘学芳.托吡酯联合左乙拉西坦对难治性癫痫患儿脑电活动、免疫球蛋白和生活质量的影响[J].,2020,(18):3537-3540 |
| 托吡酯联合左乙拉西坦对难治性癫痫患儿脑电活动、免疫球蛋白和生活质量的影响 |
| Effects of Topiramate Combined with Levetiracetam on EEG Activity, Immunoglobulin and Quality of Life in Children with Intractable Epilepsy |
| 投稿时间：2019-12-24 修订日期：2020-01-21 |
| DOI：10.13241/j.cnki.pmb.2020.18.031 |
| 中文关键词: 托吡酯 左乙拉西坦 难治性癫痫 脑电活动 免疫球蛋白 生活质量 |
| 英文关键词: Topiramate Levetiracetam Intractable epilepsy EEG activity Immunoglobulin Quality of life |
| 基金项目:河北省卫生厅科研基金项目（20160433） |
|
| 摘要点击次数: 806 |
| 全文下载次数: 472 |
| 中文摘要: |
| 摘要 目的：探讨托吡酯联合左乙拉西坦对难治性癫痫患儿脑电活动、免疫球蛋白和生活质量的影响。方法：选取2014年5月~2019年5月期间我院收治的80例难治性癫痫患儿，按照随机数字表法将患儿分为研究组（n=40）、对照组（n=40），均予原抗癫痫药物治疗方案，并积极预防并发症，在此基础上，对照组患儿给予托吡酯治疗，研究组在对照组的基础上联合左乙拉西坦治疗，比较两组患儿疗效、脑电活动、免疫球蛋白水平、不良反应、生活质量。结果：研究组治疗3个月后的临床总有效率为90.00%（36/40），高于对照组的70.00%（28/40）（P<0.05）。两组患儿治疗3个月后癫痫样放电量、α波、β波、θ 波、δ 波数量均下降，且研究组低于对照组（P<0.05）。两组患儿治疗3个月后免疫球蛋白A（IgA）、免疫球蛋白G（IgG）水平均升高，且研究组高于对照组（P<0.05）；两组患儿治疗3个月后免疫球蛋白M（IgM）水平未见显著变化，且组间比较无差异（P>0.05）。两组患儿治疗3个月后发作担忧、社会功能、情绪、精力等评分均升高，且研究组高于对照组（P<0.05）。两组不良反应发生率对比未见统计学差异（P>0.05）。结论：难治性癫痫患儿经托吡酯联合左乙拉西坦治疗后，患儿脑电活动得到有效控制，患儿免疫功能及生活质量均得到有效改善，用药安全性较好，具有一定的临床应用价值。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical effect of topiramate combined with levetiracetam on EEG activity, immunoglobulin and quality of life in children with intractable epilepsy. Methods: 80 children with intractable epilepsy who were admitted to our hospital from May 2014 to may 2019 were selected, they were divided into study group (n=40), control group (n=40) according to the method of random number table. All patients were treated with the original antiepileptic drugs, and actively prevented complications, on the basis of them, Children in the control group were treated with topiramate, while those in the study group were treated with levetiracetam on the basis of the control group. The therapeutic effect, EEG activity, immunoglobulin level, adverse reactions and quality of life were compared between the two groups. Results: The total clinical effective rate of the study group was 90.00% (36/40), which was higher than 70.00% (28/40) of the control group (P<0.05). 3 months after treatment, the epileptiform discharge, α wave, β wave, θ wave and δ wave of the two groups were all decreased, and those of the study group were lower than those of the control group (P<0.05). The levels of immunoglobulin A (IgA) and immunoglobulin G (IgG) in the two groups increased at 3 months after treatment, and those of the study group were higher than those of the control group (P<0.05). There was no significant change in immunoglobulin M (IgM) in the two groups at 3 months after treatment, and there was no difference between the two groups (P>0.05). The scores of anxiety, social function, emotion and energy were all increased in the two groups at 3 months after treatment, and those of the study group were higher than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: After treatment with topiramate and levetiracetam, the EEG activity of children with intractable epilepsy is effectively controlled, the immune function and quality of life of children are effectively improved, and the drug safety is good, which has certain clinical application value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
